• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Managing Metastatic HER2+ Breast Cancer in Greece

Bioengineer by Bioengineer
October 1, 2025
in Cancer
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In the ongoing battle against metastatic HER2-positive breast cancer, a new in-depth study from Greece sheds crucial light on the real-world management and therapeutic outcomes beyond the initial treatment phase. This investigation, titled the togetHER study, analyzes data from patients receiving second-line and subsequent therapies, offering a timely look at clinical realities before new guidelines reshaped treatment landscapes globally.

HER2-positive metastatic breast cancer presents a particularly aggressive disease subtype, marked by overexpression of the human epidermal growth factor receptor 2 (HER2), which promotes tumor growth. The integration of targeted therapies, especially trastuzumab and pertuzumab, dramatically improved survival rates, but resistance and disease progression remain vexing challenges once first-line regimens fail.

The togetHER study, conducted across eighteen oncology centers in Greece from 2015 through 2018, retrospectively compiled clinical records of 122 adult female patients who began second-line treatment (2LT) for HER2+ metastatic breast cancer during this period. Importantly, these treatments predate the incorporation of newer agents like trastuzumab deruxtecan and tucatinib into second-line strategies, providing a baseline for evaluating past therapeutic approaches.

Among the cohort, a majority (68%) presented with recurrent metastatic breast cancer, highlighting the chronic and relapsing nature of this malignancy. A notable finding concerns the subset of patients retested for HER2 status at both early and metastatic stages. Approximately 27% experienced a shift from HER2-negative to HER2-positive status, highlighting the molecular heterogeneity and dynamic tumor evolution that can complicate treatment decisions.

Patient demographics at the outset of second-line therapy revealed a median age of 57 years. The hormonal receptor landscape showed over 63% of patients were hormone receptor-positive, emphasizing the dual-pathway involvement that oncologists must navigate with combination endocrine and anti-HER2 therapies.

Metastatic spread distribution provided a comprehensive view of disease burden: bone lesions were the most frequent at 56.6%, followed closely by lung metastases at 44.3%, liver involvement at 41%, and brain metastases affecting nearly 30% of patients. This metastatic dispersion underscores the systemic and multifaceted challenge faced in managing HER2+ breast cancer at advanced stages.

In treatment patterns, the near-universal use of anti-HER2 agents in first and second-line therapies (greater than 90%) affirms adherence to evolving standards of care. Nonetheless, usage rates dwindled slightly through third and fourth lines, signaling potential therapeutic limitations or shifts in clinical strategy as resistance develops.

Endocrine therapy administration remained conspicuously low, hovering between 5.9% and 12.3% across later lines. This low uptake may mirror the predominance of chemotherapy or targeted anti-HER2 regimens in later treatment stages, or possibly reflect patient-specific tumor biology that limits hormone therapy efficacy.

Conversely, chemotherapy use amplified in later lines, rising from 30.3% in second-line treatment to nearly 48% in third and fourth lines, highlighting the entrenched role of cytotoxic agents to combat advanced disease progression despite earlier targeted interventions.

The survival outcomes painted a sobering picture: median progression-free survival (PFS) declined with each treatment line, registering 7.7 months for second-line, 6.4 months for third-line, and only 5.6 months by the fourth line. This pattern elucidates the diminishing returns from conventional treatments over time.

Moreover, median overall survival across the study population was approximately 25 months post-second-line treatment initiation, a figure that reflects the limited life expectancy still faced by many despite therapeutic advancements.

One striking yet understudied aspect was the infrequent retesting of HER2 expression following the commencement of second-line treatment—only eight cases recorded such reassessment. This practice gap could have significant implications for tailored therapies, as tumor biology may further evolve under treatment pressure.

The clinical implications emerging from the togetHER study resonate beyond Greek oncology circles. They reveal persistent unmet needs despite guideline-adherent therapy, underscoring the urgency for innovative treatments to improve long-term outcomes for metastatic HER2+ breast cancer patients.

Recent advances such as antibody-drug conjugates and novel tyrosine kinase inhibitors have reshaped treatment algorithms elsewhere, but this retrospective Greek cohort provides a critical foundation against which future real-world outcomes can be benchmarked.

The study’s retrospective design, though limiting causal inferences, robustly reflects everyday clinical practice rather than controlled trial settings, lending valuable insights into patient management variability, drug utilization patterns, and survival metrics.

Understanding how metastatic HER2+ breast cancer adapts and resists therapy is crucial to design more effective sequential therapeutic strategies. The togetHER study’s comprehensive data coverage—from molecular retesting patterns to metastatic site prevalence—enriches this understanding.

Ultimately, this work calls for heightened integration of translational research with clinical care, promoting biomarker re-evaluation during treatment and broadening access to evolving therapeutic options.

As the oncology community builds upon these findings, the hope remains that precision medicine approaches, empowered by real-world evidence like the togetHER study, will meaningfully extend and improve the quality of life for patients confronting metastatic HER2-positive breast cancer.

Subject of Research: Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond.

Article Title: Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study).

Article References: Korantzis, I., Koumarianou, A., Rapti, V. et al. Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study). BMC Cancer 25, 1473 (2025). https://doi.org/10.1186/s12885-025-14791-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14791-9

Keywords: HER2-positive breast cancer, metastatic breast cancer, second-line treatment, trastuzumab, pertuzumab, chemotherapy, progression-free survival, overall survival, endocrine therapy, real-world study

Tags: cancer treatment resistance challengeschronic relapsing breast cancerclinical outcomes in HER2+ patientsGreece oncology studyHER2 retesting in metastatic casesmetastatic HER2-positive breast cancerpatient outcomes in metastatic diseasereal-world cancer managementsecond-line breast cancer therapiestherapeutic strategies for breast cancertogetHER study findingstrastuzumab and pertuzumab effectiveness

Tags: Greece oncology studymetastatic HER2-positive breast cancerReal-world evidencesecond-line therapy outcomestogetHER study
Share12Tweet8Share2ShareShareShare2

Related Posts

Early-Onset Gastric Cancer Trends in BRICS

October 1, 2025

High-Frame Ultrasound Reveals Liver Cancer Insights

October 1, 2025

Ohio State Study Reveals Protein Quality Control Breakdown as Key Factor in Cancer Immunotherapy Failure

October 1, 2025

Machine Learning Radiomics Predicts Pancreatic Cancer Invasion

October 1, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    90 shares
    Share 36 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    66 shares
    Share 26 Tweet 17
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    64 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Autoimmune Attack on C9orf72 Linked to ALS

Exploring Chloride Effects on Stainless Steel Corrosion

Early-Onset Gastric Cancer Trends in BRICS

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.